Physician profile
David Boyce
NPI 1265961908
$1,508.99
in general payments reported to CMS, 2019-2025
29 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $130 · 2023: $697 · 2024: $371 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.95 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $369.00 | 2023-2024 | Reflexion Medical Radiotherapy System |
| Merck Sharp & Dohme LLC | $227.78 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $95.53 | 2023-2025 | Libtayo |
| Eisai INC. | $87.57 | 2022-2025 | |
| Daiichi Sankyo INC. | $70.14 | 2022-2025 | Enhertu |
| Myriad Genetic Laboratories, INC. | $68.45 | 2023 | Myrisk |
| Janssen Biotech, INC. | $48.35 | 2023-2025 | Rybrevant, Imbruvica |
| Genentech USA, INC. | $47.09 | 2023 | Tecentriq, Alecensa, Phesgo |
| Amgen INC. | $47.08 | 2023 | Kyprolis |
| Novartis Pharmaceuticals Corporation | $40.95 | 2024 | |
| Sobi, INC | $39.94 | 2023-2024 | |
| Astellas Pharma US INC | $34.64 | 2025 | Xtandi |
| Abbvie INC. | $34.26 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $27.17 | 2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $24.42 | 2024 | Onivyde |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $22.92 | 2024 | Tivdak |
| Karyopharm Therapeutics INC. | $21.15 | 2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $20.98 | 2025 | |
| Tersera Therapeutics LLC | $19.80 | 2022 | |
| Geron Corporation | $18.65 | 2024 | Rytelo |
| Incyte Corporation | $18.46 | 2025 | Jakafi |
| Dendreon Pharmaceuticals LLC | $17.89 | 2023 | Provenge |
| Seagen INC. | $17.69 | 2022 | |
| Morphosys, US INC. | $17.60 | 2023 | Monjuvi |
| Puma Biotechnology, INC. | $15.53 | 2023 | Nerlynx |
| Emd Serono, INC. | $15.41 | 2023 | Bavencio |
| Adc Therapeutics America, INC. | $13.81 | 2023 | |
| Lilly USA, LLC | $13.55 | 2023 | Jaypirca, Retevmo, Verzenio |
| Exelixis INC. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.